Percutaneous absorption of betamethasone-17, 21-dipropionate and salicylic acid during the treatment of psoriasis and eczema.
The percutaneous absorption of betamethasone-17, 21-dipropionate and salicylic acid was studied after one and two weeks' treatment of psoriaris and eczema. The treated areas varied between 8 and 41 dm2. No change in the plasma cortisol levels was detectable by the routinely used laboratory method. The treatment gave no detectable salicylate concentrations in plasma.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004485:Eczema / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism; D012459:Salicylates / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D012869:Skin Absorption; D013997:Time Factors
D012459:Salicylates; D001623:Betamethasone; D006854:Hydrocortisone